Price
No data yet.
Social Signal Score
Analyst Ratings
31 analystsRevenue
$10.81M-95.59%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David R. Lukes
- Sector
- Real Estate
- Industry
- REIT - Retail
- Employees
- 155
- Beta
- 1.02
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -10.67
Financials
Revenue
$10.81M-95.6%Net Income
$-1.30MEBITDA
$2.71M-98.4%Free Cash Flow
$-11.29M-109.6%EPS (diluted)
$-0.02Shares Outstanding (diluted)
52.45M+14.8%Operating Expenses
$9.23MCash & Debt
$238.93MReturn of Capital
$35.0KRevenue by Segment (annual)
$5.00MDividend per Share
$1.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $123.17M | $177.86M | $3.39 |
| 2024 | $277.47M | $531.82M | $9.81 |
| 2023 | $452.62M | $265.70M | $4.85 |
| 2022 | $479.22M | $168.72M | $2.96 |
| 2021 | $532.86M | $124.94M | $2.04 |
| 2020 | $460.33M | $35.72M | $0.74 |
| 2019 | $507.10M | $100.70M | $2.20 |
| 2018 | $654.86M | $-109.30M | $-2.37 |
| 2017 | $879.45M | $-241.69M | $-5.26 |
| 2016 | $969.51M | $60.01M | $1.31 |
| 2015 | $995.10M | $-72.17M | $-1.60 |
| 2014 | $953.77M | $117.28M | $2.00 |
| 2013 | $888.79M | $-10.18M | $-0.25 |
| 2012 | $800.38M | $-25.82M | $-0.72 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.98
- Implied price
- $89.69
- Return from $3.42
- 92.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $44.59 — today's price is already 92.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 60.8% | 68.2% | 74.4% | 79.9% | 84.7% |
| 3.0% | 69.0% | 76.7% | 83.3% | 89.0% | 94.2% |
| 8.0% | 77.2% | 85.3% | 92.2% | 98.2% | 103.6% |
| 13.0% | 85.4% | 93.9% | 101.1% | 107.4% | 113.0% |
| 18.0% | 93.6% | 102.5% | 110.0% | 116.6% | 122.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
96Social Signal Score
Mentions (5)
- Newsglobenewswire.com·3d ago·Neutral
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at …
View source ↗ - Newsbusinesswire.com·4d ago·Negative
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant adva…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026 NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Canc…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer pa…
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Candel Therapeutics to Present at the SITC 2026 Annual Meeting NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite i…
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.10 per share
Typical surprise +116.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.03 vs $-0.11beat
- Thu, May 7$0.02 vs $-0.11beat
- Thu, Feb 26$2.55 vs $-0.24beat
- Wed, Nov 5$-0.13 vs $-0.26beat
- Tue, Aug 5$0.88 vs $-0.16beat
- Wed, May 7$0.06 vs $-0.11beat
Estimates and results for SITC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SITC officers and directors.
- Bought
- —
- Sold
- $60.2m
0 trades
22 trades
- Cattonar John Msold
- Sweeney Dawn M.sold
- Sweeney Dawn M.sold
- Lukes David Rsold
- Lukes David Rsold
- Fennerty Conorsold
- Otto Alexandersold
- Otto Alexandersold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (328d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 11, 2018 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.